Actithera
34 employees on LinkedIn · 8 known investors
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
Founders & leadership
DD
Darshan DalalinChief Medical Officer
Investors · 8
Hadean VenturesOslo
M VenturesLos Angeles · $10.8M
Sofinnova PartnersParis · $540K – $27M
4BIO Capitalreported · 2 sourcesLondon
Bioqube VenturesreportedBrussels · $108K – $6.5M
Also in the syndicate · 3
Arkin Bio Ventures IIInnovestor's Life Science FundSurveyor Capital
Funding
SEC filings, press & company announcements$75.5M disclosed across 1 round · 2025
- $75.5Mseries AJul 2025 · 3 sources
4BIO Capital (lead), Hadean Ventures (lead), M Ventures (lead), Sofinnova Partners (lead), Arkin Bio Ventures II, Bioqube Ventures, Innovestor's Life Science Fund, Surveyor Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Actithera do?
- Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
- Who are Actithera's investors?
- Actithera's investors include Hadean Ventures, M Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures.
- How much funding has Actithera raised?
- Actithera has disclosed $75.5M raised across 1 round.